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Introduction: Iron is essential in bioenergy production, immune system efficacity 
and central nervous system development. In Chronic Heart Failure (CHF) patients, ID 
impairs functional capacity, worsens quality of life and increases mortality. There is no 
data on identification and correction of ID with intravenous ferric carboxymaltose 
(ivFCM) in CHF patients with midrange and preserved ejection fraction (HFmr/pEF). 
Methods: Between 2015 and 2016 we identified and characterized symptomatic 
HFmr/pEF patients submitted to ivFCM treatment for ID correction with or without 
anemia and, compared them to the CHF patients with reduced ejection fraction (HFrEF) 
treated on the same period. Then, between 2015 and 2018, we investigated the evolution 
of HFmr/pEF patients’ NYHA class, NTproBNP and kidney function, at three and six 
months after treatment. Results: In the comparison study, 52 CHF patients with ID were 
evaluated: mean age 86 years, 69% were men, 34.6% had HFrEF and 65.4% HFmr/pEF. 
90,4% had anemia. 13% and 23% of HFrEF and HFmr/pEF had respectively functional 
ID. HFmr/pEF patients had less ischemic heart disease (44% and 78%) and less diabetes 
mellitus (26% and 44%). No difference was seen in other comorbidities. In the evaluation 
study of patients submitted to ivFCM, 56 patients were included. 83% had absolute ID, 
75% patients were anemic. 50% in NYHA class II and 46% in class III. NTproBNP was 
6492pg/mL and eGFREPI was 47,8mL/min/m^2. At three and six months, 59% and 61% 
were in NYHA class II and 39% and 37% in class III. NTproBNP was 5331pg/mL and 
4000pg/mL, the eGFREPI was 45,8mL/min/m^2 and 45,8mL/min/m^2. Conclusion: ID 
is per se poorly evaluated in routine practice. At three and six months after treatment with 
ivFCM, although no significant changes were seen in eGFREPI, a functional 
improvement, as assessed by the NYHA class, and a reduction of NTproBNP levels were 
observed.  








Introdução: O ferro é essencial para a produção de bioenergia, eficácia do sistema imu-
nitário e desenvolvimento do sistema nervoso central. Em pacientes com Insuficiência 
Cardíaca Crónica (ICC), o défice de ferro (DF) compromete a capacidade funcional, piora 
a qualidade de vida e aumenta a mortalidade. Não há dados sobre a identificação do DF 
e correção com carboximaltose férrica intravenosa (CMFiv) em pacientes com fração de 
ejeção intermédia e preservada (ICFEi/p). Métodos: Entre 2015 e 2016, identificámos e 
caracterizámos os pacientes sintomáticos com ICFEi/p que realizaram CMFiv para cor-
reção do DF, com ou sem anemia, e comparámo-los com os pacientes com ICFEr tratados 
no mesmo período. Depois, entre 2015 e 2018, examinámos a evolução dos pacientes 
com ICFEi/p face à sua classe NYHA, porção N-terminal do péptido natriurético tipo B 
(NTproBNP), e função renal aos três e seis meses após o tratamento. Resultados: No 
estudo de comparação, 52 pacientes com ICC e DF foram avaliados: idade média 86 anos, 
69% eram homens. 34,6% apresentavam ICFEr e 65,4% ICFEi/p. 90,4% tinha anemia. 
DF funcional estava presente em 13% e 23% de ICFEr e ICFEi/p, respetivamente. Os 
pacientes com ICFEi/p tinham menos doença arterial coronária (44% e 78%) e menos 
diabetes mellitus (26% e 44%). Não se observaram diferenças nas outras comorbidades. 
No estudo de seguimento dos pacientes submetidos a CMFiv, identificámos 56 pacientes. 
83% tinha DF absoluto e 75% anemia. 50% na classe II da NYHA e 46% na classe III. 
NTproBNP foi 6492pg/mL e a eGFREPI foi de 47,8mL/min/m^2. Aos três e seis meses, 
59% e 61% estavam na classe II da NYHA e 39% e 37% na classe III. O NTproBNP foi 
5331pg/mL e 4000pg/mL, e a eGFREPI foi 45,8mL/min/m^2 e 45,8mL/min/m^2. Con-
clusão: O DF é per si subavaliado na prática clínica. Aos três e seis meses após o trata-
mento com CMFiv, não observámos alterações significativas na eGFREPI, e constatámos 
uma melhoria funcional, conforme avaliada pela classe NYHA, bem como uma redução 
dos níveis de NTproBNP.  
Palavras-chave: insuficiência cardíaca crónica deficiência ferro 
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Iron: in the center of bioenergy production, central nervous system performance 
and immunological processes 
 
Iron ability to interconvert between ferric (Fe3+) and ferrous (Fe2+) forms makes 
it an essential cofactor for a wide variety of important cellular processes, such as 
oxygen transport, respiration, the tricarboxylic acid cycle, lipid metabolism, gene 
regulation and DNA synthesis.1,2 In order to execute such multiple tasks, iron is 
incorporated in the heme group of hemoglobin, myoglobin and cytochromes, or is 
associated to nonheme moieties or iron-sulfur (Fe-S) motifs. Not surprisingly, iron is 
considered an essential nutrient for virtually all organisms.4  The maintenance of 
normal iron metabolism is particularly important for cells that are characterized by 
high mitogenic potential (neoplastic cells, hematopoietic cells, including immune 
competent cells) and high energy demand (hepatocytes, adipocytes, renal cells, 
immune cells, skeletal myocytes, and cardiomyocytes).2–4 
 
The elementary iron was firstly recognized as a critical component in systemic 
oxygen delivery and utilization. In fact, iron contributes to erythropoiesis and iron 
deficiency (ID) decreases oxygen-carrying capacity of the blood through reduced 
hemoglobin levels, the classic sign of ID.1,5 Furthermore, severe dietary ID, in 
addition to causing anemia, decreases the capacity of skeletal muscle to consume 
oxygen and produce ATP, i.e. tissue oxidative capacity.6 The tissue oxidative 
capacity, which determines endurance, energy efficiency, and submaximal exercise 
effort, is impaired proportionally across the whole spectrum of ID even when 
hemoglobin is normal.5 Likewise, it has been demonstrated that cellular ID results in 
a reduced activity of Fe-S cluster-based complexes in the mitochondria of human 
cardiomyocytes and is associated with impaired mitochondrial respiration and 
morphology, ATP production and, cardiomyocyte contractility and relaxation. Iron 
supplementation can revert these effects.7 In addition to reduced physical 
performance, fatigue is also closely associated with anemia and ID. Its correction 
improves mental quality of life, cognitive functions, self-rated alertness, contentment 
and calmness.8  
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Biologically, iron is required for proper myelination of the spinal cord and white 
matter of cerebellar folds and, it is a cofactor for several enzymes involved in 
neurotransmitter and DNA synthesis. As whole-brain iron content drops 15% below 
normal, biological and behavioral alterations occur due to changes in the 
dopaminergic system.2,9,10 There is compelling evidence that within critical periods, 
i.e. 6- to 24-month-old infants, ID have long-term effects on cognitive, motor, 
socioemotional and neurophysiologic development.11 Moreover, in women aged 18 
to 35 years the severity of ID was linked with a reversible decreased cognitive 
performance and increased time to complete learning, memory, and attention tasks.12  
 
Finally, being iron a critical component of peroxide-generating enzymes and 
nitrous oxide–generating enzymes that are critical for the proper enzymatic 
functioning of immune cells, it is likely involved in the regulation of cytokine 
production and second-messenger systems.2 Also, ID results in decreased T-
lymphocyte numbers and in decreased T-lymphocyte blastogenesis and mitogenesis 
in response to mitogens.9 However, the role of iron in the immune system is 
ambiguous as the host must effectively withhold iron from pathogens and 
simultaneously provide a supply of iron that is not limiting to its immune system.2,13 
An example of how iron overload might be disadvantageous was demonstrated by 
parenteral iron treatment association with life-threatening sepsis when given in the 
early neonatal period.14 Despite proven reversible functional immunological defects, 
a clinically important relationship between states of ID and susceptibility to infections 
remains controversial.14 Studies have shown us that the risk, if any, of intravenous 
iron causing infection and related morbidity and mortality is probably very small.15 
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 Figure 1. ID impact in bioenergy production, erythropoiesis, immune system and 




From a nutritional viewpoint, both iron depletion and excess have dramatic 
consequences and great epidemiological significance. Indeed, in conformity with 
northern Europe, absolute ID is present in as much as 32% of the Portuguese 
population.16 There are no current global figures for ID, but using anemia as an 
indirect indicator it can be estimated that most preschool children and pregnant 
women in non-industrialized countries, and at least 30-40% in industrialized 
countries, are iron deficient. The estimated prevalence of ID worldwide is twice as 
high as that of iron-deficiency anemia.17 Not only it is the primary nutritional disorder 
in the world, but also hereditary hemochromatosis, which causes excess iron 
accumulation, is one of the most common genetic disorders - nearly 10% of the white 
population carries the most prevalent C282Y HFE mutation.3  
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In order to maintain its homoeostasis, there are two major pathways which must 
be elucidated, the first being the mechanism of iron absorption, more specifically in 
the duodenum and proximal jejunum and, the second the regulation of iron 
bioavailability, which is mainly adjusted by the reticuloendothelial system. 
 
There are two different iron absorption pathways: one for heme-bound iron, 
mostly bound to porphyrins in meat-based foods, and another for non-heme iron, 
mostly found in vegetables. Heme-iron constitutes only 10% of dietary iron, but 
because of greater bioavailability it represents 30% of the total absorbed iron, being 
absorbed via a specific membrane transporter, the heme carrier protein-1.18,19 Non-
heme iron is mostly found in the ferric form and is reduced to the ferrous form by a 
luminal ferrireductase, being thereafter transported into the enterocyte via a divalent 
metal ion transporter DMT1.3 Afterwards, ferrous iron may be either exported 
through the basolateral membrane of the enterocyte by ferroportin-1 (FPN1) or it is 
stored in the form of ferritin inside the enterocyte being lost once the cell is sloghed.1 
When it follows the FPN1 way, an accompanying membrane hephaestin oxidizes 
ferrous into ferric iron, which is then released into the circulation and bound to 
transferrin. It may then be incorporated into cells by coupling with Transferrin 
Receptor 1 (TFR1), forming a complex that follows endocytosis.18 Alternatively, 
ferrous iron  may be directly uptaken by DMT1, which is expressed in most tissues.20 
 
The absorption of intestinal iron is regulated in several ways. Firstly, after a 
dietary iron bolus there is a direct resistance of absorptive enterocytes to iron, a 
mechanism referred as the dietary regulator.1 Secondly, hepcidin, an early 
inflammatory marker expressed predominantly in the liver, inactivates FPN1 
promoting the sequestration of iron in the enterocyte and, subsequent lost.20 
   
Although the major entry site for iron into the body is via dietary absorption of 
heme and non-heme bound iron in the duodenum, the major cellular system 
responsible for a sufficient supply of iron for erythropoiesis is the reticuloendothelial 
system.20 Approximately 95% of the daily needs of iron for erythropoiesis originates 
from this system, where activated macrophages phagocytose senescent erythrocytes 
for the recycling of iron. Once iron enters the macrophage cytoplasm it is either stored 
within ferritin, utilized upon incorporation into iron-containing enzymes or exported 
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and transferred to the circulation by FPN-1. Importantly, FPN-1, highly expressed in 
enterocytes, Kupffer cells and spleen macrophages., is so far the only known iron 
exporter, therefore the efficacy of iron recycling from erythrophagocytosis is linked 
to the expression of this protein. The earlier mentioned hepcidin plays a pivotal role 
by binding to this unique iron exporter leading to its internalization and degradation. 
Of note, the hepatic expression of hepcidin is stimulated by interleukin-6 and 
lipopolysaccharide. This results in a blockage of iron export and subsequent 
monocyte/ macrophage iron retention.20,21  
 
Not only hepcidin but also proinflammatory stimuli, such as Interferon-γ, 
lipopolysaccharide and TNF-α, also induce the retention of iron in macrophages by 
up-regulating the expression of DMT1 expression and down-regulating the 
expression of FPN1, promoting simultaneously the uptake of ferrous iron while 
inhibiting its exportation.20,21 
In summary, cytokines and hepcidin inhibit iron export from macrophages via 
downregulation of FPN1 expression, resulting in iron retention within cells of the 
reticuloendothelial system and an iron restricted erythropoiesis.2,18,22  
 
 
Figure 2. Iron metabolic pathway and hepcidin regulation; FPN1, ferroportin-1; 
HCP1, heme carrier protein-1; TFR1 Transferrin Receptor 1. Adapted from Weiss 
G. Anemia of Chronic Disease, The New England Journal of Medicine, 2005:13. 
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Evaluation of Iron Deficiency 
 
The most widely used screening measurement is Serum Ferritin (SF) which in the 
absence of inflammation, is the best noninvasive estimate of body iron stores. A 
ferritin level of less than 45 mg/L is 85% sensitive and 92% specific for ID.23 
However, because it is an acute phase protein, SF is increased independent of iron 
status by acute or chronic inflammation. It is also unreliable in the setting of 
malignancy, hyperthyroidism, liver disease, and heavy alcohol intake.24 Another 
widely used screening tool is the degree of iron saturation of plasma transferrin 
(TSAT) calculated as the ratio of the plasma iron to total iron-binding capacity.25 
Marked diurnal variation in plasma iron values and the numerous clinical disorders 
that affect the transferrin saturation limit its reliability.26 Other interesting markers are 
the serum transferrin receptor (sTfR), the sTfR/log ferritin ratio, the reticulocyte 
hemoglobin content (CHr), reticulocyte hemoglobin content equivalent (Ret-He), and 
the erythrocyte zinc protoporphyrin (ZPP). 
 
The sTfR is a transmembrane glycoprotein that transfers circulating iron into 
developing red cells. Under iron-deficient conditions there is an increased 
concentration of surface sTfR. sTfR concentration appears to be a specific indicator 
of IDE that is not confounded by inflammation24. However, this assay was found to 
have a specificity of 84% and a positive predictive value of only 58% in a population 
of patients likely to be typical of the most difficult diagnostic environments for 
assessing iron status.27 When hemolysis or megaloblastosis can be excluded the sTfR 
measurement should be an attractive alternative to more conventional tests of iron 
status.28 Attempts to combine ferritin and sTfR results have led to the sTfR/log ferritin 
ratio,  which was found to be highly sensitive and 93% specific for the diagnosis of 
ID.23 On the other hand, there was a significant number of patients in a “diagnostic 
grey zone” who could not be correctly classified.29  
 
Flow cytometric analysis of reticulocytes allows determination of the mean 
cellular hemoglobin content of reticulocytes (CHr) or percentage of hypochromic 
reticulocytes (%HRC). The former is a premature phase marker (48 hours) while the 
latter reflects a longer period (20-120 days) of iron restricted erythropoiesis.28 The 
%HRC is the best-established variable for the identification of functional ID and thus 
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has the greatest level of evidence, while CHr is the next most established option. 
Falsely normal values of the CHr can be observed with an elevated MCV or 
thalassemia, but the main limitation to its wider use is that it can be measured with 
only one model of analyzer (Bayer ADVIA®).30 Among patients undergoing bone 
marrow examination for diagnostic purposes CHr had a better predictive value for 
iron depletion than MCV, serum ferritin or transferrin saturation values.30 
 
An alternative measure of reticulocyte hemoglobin content, Ret-He (reticulocyte 
hemoglobin equivalent), is available on some analyzers manufactured by the Sysmex 
Corporation®. Ret-He alone was able to distinguish iron-deficient and iron-sufficient 
subjects using a cut-off of 25pg with reasonable sensitivity. Although less sensitive 
(80% agreement with sTfR and sTfR/log ferritin values), a Ret-He cut-off of 25 pg 
may help to distinguish absolute ID (values <25 pg) from functional ID (values >25 
pg). With a Ret He cutoff level of 27.2 pg, ID could be diagnosed with a sensitivity 
of 93.3%, and a specificity of 83.2%. Ret-He is a reliable marker of cellular 
hemoglobin content and can be used to identify the presence of ID states.31 
 
A simple and reliable measurement of IDE is the ZPP - the incorporation of iron 
into protoporphyrin IX is the final stage of heme synthesis and, an increase in ZPP is 
an indicator of defects at any point along this pathway. A major advantage of this well 
stablished assay is the ability to measure the ratio ZPP/heme directly on a drop of 
blood using a dedicated portable instrument called a hematofluorimeter. The ZPP is 
not widely used in large clinical laboratories, partly because of the difficulty in 
automating the assay. Due to lack of specificity, ZPP should not be used in isolation 
as a diagnostic test, but once a diagnosis is made it may be used to monitor response 
to therapy. The ZPP concentration reflects the entire circulating red cell population 
and is thus less sensitive than %HRC or CHr to acute changes in iron availability.30 
 
In the setting of iron restricted erythropoiesis there are two different conditions to 
be distinguished: absolute ID and functional ID.28 Absolute ID reflects depleted iron 
stores, often with intact iron homoeostasis mechanisms and erythropoiesis. The 
commonest causes are: low-dietary iron, impaired gastrointestinal absorption, and 
blood loss.25 Currently, although the generally accepted SF cut-off level to diagnose 
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absolute ID is 30 mg/L, a higher value, 100 mg/L,  may provide optimal sensitivity 
and specificity for the detection of depleted iron stores in inflammatory cohorts.26,28,32  
 
A distinct situation is functional ID, which develops during increased 
erythropoiesis mediated either by endogenous erythropoietin responses to anemia, or 
by therapy with erythropoiesis-stimulating agents (ESAs): the iron supply, though 
adequate for baseline erythropoiesis, cannot meet the erythron requirements of 
supraphysiologic erythropoiesis. In these patients, the TSAT may be 20% as the 
hungry bone marrow strips iron off the circulating transferrin faster than the 
transferrin can replenish it with iron released from stores. The serum ferritin, which 
reflects iron stores, may be normal or elevated. This is a problem of supply and 
demand, not total body ID.25,26,28 
 
An extreme case of functional ID is known as reticuloendothelial blockade and 
usually occurs in the setting of acute or chronic inflammation/infection, thus the 
designation anemia of chronic disease. This often correlates with a high C-reactive 
protein level and/or a high erythrocyte sedimentation rate. As explained above, the 
molecular mechanisms that underlie the redistribution of iron during inflammation 
center on the cytokine-stimulated overproduction of hepcidin, which “locks up” iron 
in the reticuloendothelial storage. As a result, transferrin-bound iron, which is 
reflected by the TSAT, is low despite a normal or elevated ferritin. When it is feasible 
to measure several indices, the initial laboratory evaluation, in addition to the SF and 
hemoglobin, should include a C-reactive protein, sTfR and/or ZPP. Due to the 
aforementioned issues it is widely accepted to define ACD as a SF≥100 mg/L and 
≤300 mg/L when TSAT ≤20%.4,25 
 
Iron Deficiency, Anemia, and Chronic Heart Failure 
 
The complex pathophysiology of Chronic Heart Failure (CHF) involves dysfunc-
tion of most body organs, including the cardiovascular, musculoskeletal, renal, neu-
roendocrine, hemostatic, immune, and inflammatory systems.33  Despite optimal con-
ventional therapy, many patients with CHF remain symptom limited, exercise intol-
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erant, and subject to high rates of mortality.34 Clinical symptomatology of CHF re-
sembles that of ID, therefore one can simply imply impaired iron homeostasis as one 
of the mechanisms underlying exercise intolerance in CHF. Interestingly, ID as an 
issue in the CHF syndrome only recently gained clinical interest, coinciding with the 
recognition of anemia as a frequent co-morbidity in CHF.35  
 
At the beginning of this century, the first report of a decrease in blood hemoglobin 
content with increasing severity of CHF was published.36 Since then, several studies 
have documented how prevalent reduced hemoglobin is, being present in one-third of 
the CHF population, and how it is independently associated with increased risk of 
hospitalization and all-cause mortality, regardless of the ejection fraction.35,37,38 The 
etiology of anemia in CHF is not yet clearly understood due to the interaction of sev-
eral elements such as: renal dysfunction, hemodilution, the angiotensin-converting-
enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARAII), chronic in-
flammation, bone marrow dysfunction, abnormal steroid metabolism, resistance to 
erythropoietin, and hematinic deficiencies, such as vitamin B12, folate and, in partic-
ular, ID.22,37  
 
The first efforts to address the correction of anemia in CHF fell short of the ex-
pectations. Despite increasing the hemoglobin level, the ESA – darbepoetin alfa – was 
shown to have no positive impact on the primary outcome of death or hospitalization 
for worsening heart failure. Furthermore, there was an increase in fatal or nonfatal 
strokes, as well as all-cause mortality.36  
 
Yet, when one door closes another one opens. Within the deranged milieu of CHF, 
iron is abnormally handled, being preferentially trafficked into storage sites and with-
drawn from the circulation and erythroid marrow, triggering functional ID, with char-
acteristic normal ferritin concentrations.4,34 In patients with CHF with reduced ejec-
tion fraction (HFrEF), ID is common, ranging between 37% and 55%,4,37,39 being 
even as high as 73% when evaluated by bone marrow aspiration in those with ad-
vanced CHF and anemia.40 Moreover, it constitutes a strong independent predictor of 
unfavorable outcome, irrespective of the presence of anemia and the severity of heart 
disease.4,22,34,40,41 Patients with ID are more frequently females, at higher New York 
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Heart Association (NYHA) class, with ischemic cardiomyopathy, a lower hemoglo-
bin and a higher NT-pro-brain natriuretic peptide (NTproBNP).4 A decreased iron 
status is associated with exercise intolerance and breathlessness on exertion, as well 
as increased disease severity as assessed by NYHA functional class and NTproBNP 
level.39 Indeed, ID is per se prognostically more ominous than anemia in CHF.4,34 
 
Although a greater number of studies have focused on HFrEF rather than CHF 
with midrange and preserved ejection fraction (HFmrEF & HFpEF), recent evidence 
has broadened the spectrum. Not only a high prevalence of ID has been confirmed in 
patients with HFmrEF (61%) and HFpEF (58.4-64%), but it has also been related to 
a reduced exercise capacity, VO2max, quality of life, worse clinical outcome, and all-
cause mortality.42,43 Accordingly, ID prevalence increases with increased severity of 
diastolic dysfunction. Interestingly, in the HFpEF group 41.1% presented with iso-
lated ID, i.e., without anemia, which reflects how it can be an unexpressed condition. 
ID is a frequent co-morbidity in patients with HFmrEF & HFpEF being associated 
with a more severe heart failure status.42,43  
 
Correction of Iron Deficiency  
 
Facing all the evidence suggesting such an impact of ID in CHF corroborated by 
the first small trials,44 a pioneer trial was brought up. FAIR-HF demonstrates how 
treating ID with intravenous ferric carboxymaltose (IV FCM) for 24 weeks in patients 
with HFrEF and ID, with or without anemia, improves symptoms, functional capacity, 
and the quality of life, as assessed by the self-reported Patient Global Assessment and 
the NYHA class.45 It also suggests an improvement in distance on the 6-minute 
walking test distance, which was later stated by the CONFIRM trial. Besides proving 
that the treatment of ID, regardless the presence of anemia, in HFrEF patients with IV 
FCM results in a sustainable improvement in functional capacity as measured over a 
1-year period using the 6-minute walking test, the CONFIRM trial notes a significant 
reduction of first hospitalization due to worsening CHF in the IV iron group.46  
 
It is worth mentioning that IV FCM, contrary to other IV formulations - iron 
dextran, ferric gluconate and iron sucrose; is dextran-free and thus does not interact 
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with dextran antibodies limiting the hypersensitivity reactions that happen with those. 
Indeed, both studies had no side effect and adverse event issues.35,47  
 
More recently, the EFFECT-HF study confirms that after 24 weeks of correction 
of ID with IV FCM in patients with HFrEF there is a beneficial effect on peak VO2, 
which has been linked with a more favorable outcome.48,49  
 
 
Whether iron repletion of ID in HFrEF could be done orally was the main idea 
behind the IRONOUT trial, which contrary to the mentioned trials, found a lack of 
effect of oral iron therapy over 16 weeks on exercise capacity, including peak VO2 
and 6-minute walking test distance and, quality of life scores, besides, it minimally 
augmented iron stores.50 Being this ID a functional ID related with high hepcidin 
levels, IV iron is advantageous over oral iron as it may bypass hepcidin actions by 
directly loading transferrin for further transport to the bone marrow.51,52 Interestingly, 
when comparing patients according to their hepcidin levels, after oral iron therapy 
those with higher hepcidin baseline levels demonstrated reduced TSAT and SF 
augmentation and an attenuated decline in soluble transferrin receptor levels, which 
corroborates that higher hepcidin levels may limit responsiveness to oral iron.50 
 
 
Table 1. Outcome results of ID correction with IV FCM in HFrEF patients; *primary 
endpoint; 6MWT, 6-minute walking test; CHF, Chronic Heart Failure; CV, 
cardiovascular; n.a., not available; NTproBNP, NT-pro-brain natriuretic peptide; PGA, 





Once perceived the impact of iron stores repletion with IV FCM in symptomatic 
patients with ID and HFrEF it is tempting to wonder whether it could be a therapeutic 
weapon in the HFmrEF & HFpEF population with ID.  Until this moment there are 
no data about ID correction with IV FCM in HFmrEF & HFpEF patients. As we 
referred above, only data on ID prevalence on different populations of CHF patients 
is available, as well as its influence on their functional capacity. 
 
Regarding this question, we collected data from symptomatic CHF patients who 
had been treated with IV FCM for correction of their anemia or ID. Within this 
population we analyzed and compared CHF patients according to their type of CHF: 
HFrEF and HFmrEF & HFpEF patients. Then we evaluated HFmrEF & HFpEF 
patients’ NYHA class, NTproBNP and glomerular filtration rate evolution at three 




Materials and Methods  
 
The present work had two steps. In the first one, study A, we focused on the 
comparison of HFpEF and HFmrEF & HF&EF patients submitted to IV FCM. On the 
second one, study B, we evaluated the follow up of HFmrEF & HFpEF patients at 
three and six months after IV FCM treatment.  
For both studies the type of CHF was determined according to the European 
Society of Cardiology recommendations, ID was designated as absolute (ferritin <100 
mcg/L) or functional (ferritin 100-299 mcg/L and saturation of transferrin <20%), anemia 
was defined according to WHO definition, microcytosis was defined as a medium 
corpuscular volume <80 fL. Chronic kidney disease was defined as eGFR EPI <60 
mL/min/m^2.  
All statistical analyses were performed by using SPSS. 
 
Study A: A population characterization  
 
Between 2015 and 2016, we identified all symptomatic CHF patients referred to 
IV FCM treatment for their ID correction. We evaluated for each patient the type of CHF 
and NYHA class, demographic characteristics, comorbidities, ongoing therapy, the 
presence of anemia and type of ID. Afterwards we analyzed the difference between 
HFrEF and HFmrEF & HFpEF patients. 
 
Study B: ID correction in HFmrEF & HFpEF, a follow up at 3 and 6 months 
 
All the symptomatic HFmrEF & HFpEF patients submitted to IV FCM for their 
ID correction, between 2015 and 2018, were identified. We evaluated their demographic 
characteristics, comorbidities, presence of anemia, type of ID, NYHA Class, NTproBNP 
level and glomerular filtration rate (assessed by eGFR EPI) before and after IV FCM 
administration at three and six months. 
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Only patients submitted to 1000 mg of IV FCM administration, who were on 
NYHA Class II or higher and with available data on their medical records before, at three 
and six months after IV FCM administration were eligible.  
For each patient we evaluated their diuretic therapy defining a daily furosemide-
equivalent dose: 40 mg of furosemide were considered equivalent to 10 mg of torasemide, 
5 mg of metolazone, 2,5mg of indapamide and 25mg hydrochlorothiazide. 
 
Results 
Study A: A population characterization  
 
During the study period, 52 patients with CHF were submitted to IV FCM: 69% 
were men, and the mean age was 86±9 years. Regarding their type of CHF: 34.6% had 
HFrEF and 65.4% had HFmrEF & HFpEF. Patients were predominantly in NYHA class 
II 55% and class III 41%, with one patient being Class I and another Class IV. 90,4% had 
anemia: 25% were microcytic. HFrEF and HFmrEF & HFpEF patients had, respectively, 
87% and 77% absolute ID, and 13% and 23% functional ID. Concerning comorbidities, 
HFrEF and HFmrEF & HFpEF had respectively: 78% and 44% ischemic heart disease, 
72% and 76% hypertension, 50% and 62% atrial fibrillation (AF), 44% and 26% diabetes 
mellitus (DM), 67% and 76% chronic kidney disease (CKD), 28% and 29% chronic 
obstructive pulmonary disease (COPD), 11% and 15% peptic ulcer disease and 22% and 
9% history of neoplasia of the digestive tract. As to their medication, 42.3% were being 
treated with antiplatelet drugs, 63.5% with anticoagulants, and 13.5% simultaneously on 
antiplatelet and anticoagulant therapy. 65.4% were on ACEi or ARAII, 26.9% on 
mineralocorticoid receptor antagonists, 86.5% on diuretics, 76.9% on beta blockers and 




Table 2. ID characterization in HFrEF and HFmrEF & HFpEF patients. 
 
 
Table 3. Comorbidity analysis of both populations – HFpEF and HFmrEF & HFpEF. 
AF, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; DM, diabetes mellitus; GI, gastrointestinal; HTN, hypertension; 
IHD, ischemic heart disease; PUD, peptic ulcer disease. 
 
Study B: ID correction in HFmrEF & HFpEF, a follow up at 3 and 6 months 
 
56 patients with HFmrEF & HFpEF and ID were identified. From these 54% (30) 
were men, the mean age was 82,5±7 years. As to their iron status 83% (47) had absolute 
ID and 17% (9) had functional ID. 75% (42) patients were anemic, with a mean 
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hemoglobin (Hb) value of 11±2,1 g/dL, of which 13% (7) were microcytic. Concerning 
their comorbidities, 25% (14) had ischemic heart disease, 70% (39) hypertension, 64% 
(36) AF, 32% (18) DM, 66% (67) CKD, 27% (15) COPD, 11% (6) peptic disease and 
14% (8) history of neoplasia of the digestive tract. Regarding their NYHA class: 50% 
(28) patients were in class II, 46% (26) in class III and 4% (2) in class IV. The average 
NTproBNP was 6492±17459 pg/mL. The mean furosemide-equivalent dose was 40,7±26 
mg per day, and the mean eGFR EPI: 47,8±22,6 mL/min/m^2. At three and six months 
after IV FCM administration: ID was absolute in 14% (6) and 22% (6) of the patients and 
functional in 17% (7) and 16% (5), with anemia being present in 57% (30) and 56% (22) 
of the patients, with a mean Hb value of 12±1,8 g/dL and 12±1,8 g/dL There was one 
patient (2%) with microcytosis. As to their NYHA Class: 59% (33) and 61% (23) patients 
were in Class II, 39% (22) and 37% (14) in Class III, 2% (1) and 3% (1) in Class IV. The 
average NTproBNP was 5331±9476 pg/mL and 4000±5262 pg/mL. The mean 
furosemide-equivalent dose was 45,8±23,4 mg and 45,6±30,0 mg per day, while the mean 
eGFR EPI: was 45,8±23,4 mL/min/m^2 and 45,8±24,8 mL/min/m^2.  
 
 






 0M 3M 6M 
Hemoglobin (g/dL) 11 ± 2.1 12 ± 1.8 12 ± 1.8 
Anemia 75% 57% 56% 
Microcytosis 13% 2% 2% 
Iron Deficiency 
          Absolute 
          Functional 
100% 31% 38% 
83% 46% 58% 
17% 54% 42% 













Progression of ID after IV FCM








Table 7. Evolution of NTproBNP, furosemide-equivalent dose and kidney function at 




Progression of NTproBNP, furosemide-equivalent dose 














Study A: A population characterization  
 
Despite the lack of recommendations for IV FCM therapy in patients with 
HFmrEF & HFpEF this type of CHF prevailed over HFrEF patients (65.4% vs 34.6%). 
Nevertheless 90% of the patients were anemic, suggesting that ID per se continues to be 
poorly evaluated and referred to treatment in daily practice. In CONFIRM-HF only 1/3 
of the population had anemia.46  
CHF patients, despite of the ejection fraction, were very elderly with a mean age 
of 86 years, significantly older than in previous studies,45,46 and with several 
comorbidities. The distribution of these was overall similar throughout both group of 
patients, except for ischemic heart disease, DM and GI Neoplasia, which were more 
prevalent in HFrEF. We only found a statistically significant value for ischemic heart 
disease (78% vs 44%, p=0,013). This finding may reflect the difference on the etiology 
of the type of dysfunction.53 On the other hand, we found a trend on functional ID being 
more prevalent in HFmrEF & HFpEF than in HFrEF (13% vs 23%). These findings are 
in agree with the latest evidence which looks into HFrEF as a disease where left 
ventricular remodeling is driven by cardiomyocyte death mainly due to ischemia, 
infection or toxicity, while the new HFmrEF & HFpEF paradigm stands noncardiac 
comorbidities, namely HTN, obesity, DM, COPD, anemia and CKD, as triggers of 
coronary microvascular endothelial inflammation and, subsequentially, cardiomyocyte 
stiffening and hypertrophy.53  
 
Study B: ID correction in HFmrEF & HFpEF, a follow up at 3 and 6 months 
 
Between 2015 and 2018 there were 56 HFmrEF & HFpEF and ID patients treated 
with IV FCM.  ID anemia was the main reason for IV FCM prescription in HFmrEF & 
HFpEF patients: only 25% of the patients didn´t have anemia. At three and six months 
after 1000 mg of IV FCM there was a discrete increase in Hb levels and a pronounced 
reduction in ID prevalence among these patients.  
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The modest increase of Hb levels raises the question, what is the etiology behind 
these patient’s anemia? Probably ID, while being a major culprit is not the only one.22 As 
we observed in study A, the prevalence of renal dysfunction, related to a lack of 
erythropoietin production, was considerably high (76%), as well as the usage of 
antiplatelet and anticoagulant drugs (42.3% and 63.5%) or the combination of both 
(13.5%), which may contribute to blood losses. Moreover 65.4% of the patients were on 
ACEi or ARAII which may inhibit the proliferation of bone marrow derived 
erythropoietic cells.54 Also, hemodilution might have influenced the degree of anemia.22 
Above all, while there were no side effect and adverse event issues, we verified 
both a functional improvement, as assessed by the NYHA class and, an appealing 
reduction of NTproBNP levels. 
Simultaneously, no changes were seen in eGFR EPI or furosemide-equivalent 
dose. The furosemide-equivalent dose was used as a surrogate of volume status. Diuretics, 
when increased, have the ability to decrease both the NYHA class and NTproBNP levels 
by decongesting the CHF patient and therefore reducing the wall stress of the left 
ventricle.55 Although it doesn’t counterbalance the lack of a control group, the absence of 
a significant change in the mean furosemide-equivalent dose allows us to expect that the 
improvement seen in the NYHA class and NTproBNP levels were not due to diuretic 
therapy adjustments, strengthening our hypothesis that it was rather due to ID correction 






Iron is a cornerstone micronutrient in bioenergy production, immune system 
efficacity and central nervous system development. Inflammation is characteristic of 
chronic diseases leading to a deranged milieu that disrupts iron metabolism contributing 
to a state of ID. In CHF patients, ID is responsible for the impairment of functional 
capacity, worse quality of life and increased mortality being per se prognostically more 
ominous than anemia. Although its identification and correction with IV FCM are 
currently recommended in HFrEF patients there is currently no data about the impact of 
IV FCM in HFmrEF & HFpEF patients.   
Our study pretends to illustrate a daily practice scenario in which symptomatic 
patients with HFmrEF & HFpEF were recognized as being ID and thereafter submitted 
to its correction with IV FCM. Despite the lack of evidence for this practice, it was still 
conducted for correction of ID anemia. In the end, we realized it was a safe treatment, 
with no adverse event issues reported and without worsening the glomerular filtration 
rate. We also observed that it led to an improvement of the symptomatic variables NYHA 
class and NTproBNP, surrogate endpoints for CHF patients.56,57 
Even though these results are noticeable, we highlight the lack of statistical 
significance of these numbers. This was a retrospective, non-randomized, nonblinded 
study with a small patient population and, therefore these results are merely suggestive 
of a potential improvement in the ID status, NYHA class and NTproBNP levels of 
HFmrEF & HFpEF patients with ID after IV FCM treatment. These findings support the 
need for prospective studies to investigate iron correction as a potential therapeutic target 
in patients with ID and HFmrEF & HFpEF.  
The FAIR-HFpEF study is an undergoing clinical trial designed to access the 
impact of IV FCM in patients with ID and HFpEF focusing on the improvement of 
symptoms and exercise capacity as measured by the 6-minute walking test, as well as the 
impact on mortality and CHF related hospitalization rates, that may shed some light on 
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